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Presence of sufficient number of functional glucose responsive β-cells is indispensable for normal glucose homeostasis. Dia-
betes mellitus is a chronic disease associated with loss or reduction of β-cell mass and not β-cell mass. MicroRNAs are small 
non-coding RNAs that are involved in different biological processes including development, cell proliferation, stress response, 
and tumor pathogenesis. MicroRNAs fine-tune the gene expression level post-transcriptionally either by mRNA degradation 
or translational repression. In the past few years, several miRNAs have been introduced as new critical players for pancreas 
development, function, and regeneration. Deregulation of several microRNAs is found in animal models of diabetes, as well as 
in diabetic patients. Therefore, it is essential to understand the roles of these microRNAs in β-cell generation and physiology, as 
well as the biological consequences of their functional impairment. Biomed Rev 2013; 24: 57-65
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INTRODuCTION
The pancreas consists of two different compartments, the 
exocrine and the endocrine cell populations. The exocrine 
compartment consists of acinar and duct cells, which are 
involved in secretion of digestive enzymes (acinar cells) and 
their transport to the duodenum (duct cells). The endocrine 
pancreas is organized in the so-called ‘islets of Langerhans’, 
functional units consisting of α-, β-, δ-, PP- and ε-cells express-
ing glucagon, insulin, somatostatin, pancreatic polypeptide 
and ghrelin, respectively (1).
Loss or reduction of β-cells mass and not β-cell mass is 
the hallmark of both type 1 and 2 diabetes mellitus, a disease 
with long-term severe complications like amputation, diabetic 
coma, and cardiovascular diseases. The final approach for dia-
betes treatment should lead to exogenous insulin-independent 
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therapy. Currently, the most common strategy toward this goal 
is replacement of β-cells using islet-transplants from donor 
pancreata. The main drawback here is the limitation of donor 
islets. In vitro generation of β-cells is a potentially reliable 
alternative method that can overcome the resource limitation of 
islet transplantation (2,3). To generate fully functional β-cells 
in vitro it is necessary to understand the mechanisms under-
lying pancreas and specifically islet and β-cell development. 
While a battery of transcription factors and signaling pathways 
are investigated in this context and their function in pancreas 
development become more and more clear (4-13), recent find-
ings have also shown that miRNAs play fundamental roles in 
pancreas and β-cells development. 
Caenorhbditis elegans was the first organism, in which 
the importance of miRNAs was discovered (14). In general, 
miRNAs act as negative regulators of gene expression. MiR-
NAs are first transcribed as pri-miRNAs, and then cleaved by 
Drosha RNAse III endonuclease to generate the pre-miRNAs 
that are about 60-70 nucleotides long (15). The pre-miRNAs 
are transported to the cytoplasm, where they are processed by 
Dicer to generate the miRNA/miRNA* double strand (16). The 
mature miRNA will be incorporated into the miRNA-induced 
silencing complex (miRISC) that finally binds to the 3’UTR 
of their target sequence, resulting in either target mRNA deg-
radation or translational repression (15,16).
In the past few years, the importance of miRNAs in regula-
tion of different developmental processes has become more and 
more evident. Several studies indicate that these micro-players 
are implicated in pancreas development as well as type 1, and 
type 2 diabetes (17-19). In this review, we discuss the multi-
ple roles that miRNAs may play during endocrine pancreas 
development and regeneration (Figure 1).
miRNAs IN PANCREAS DEVELOPMENT
Analyses of pancreas-specific Dicer knockout mice revealed 
that miRNAs are essential for pancreas development and β-cell 
formation (20). Thus, the depletion of Dicer, the enzyme that 
is necessary for biosynthesis of microRNAs, in Pdx1-positive 
pancreatic progenitors, is accompanied with severe defects of 
pancreatic tissue, especially due to the loss of endocrine cells. 
The most affected cell type was the β-cell, exhibiting 94 % 
reduction compared to wild type littermates (20). Furthermore, 
the early loss of dicer in pancreatic progenitors leads to upregu-
lation in Hes1 expression, and resulting in decreased numbers 
of Ngn3-positive endocrine cells. In addition, following inac-
tivation of Dicer in β-cells, reduction of Insulin transcription, 
and content, as well as hyperglycemia were noticed (21). 
Moreover, conditional knockout of Dicer in β-cells provokes 
disturbance in insulin secretion, as well as progressive deple-
tion of insulin producing cells, suggesting a role for miRNAs 
in β-cell survival (22,23). In the pancreata of these mice, the 
cell adhesion molecule E-cadherin is also deregulated and as a 
consequence, the islet architecture is disrupted (22). Recently, 
analyses of Dicer-deficient endocrine progenitors indicate 
that following the first neonatal days hormone expression is 
abolished. Instead, the expression of neuronal genes, such 
as tyrosine hydroxylase or stathmin-like 2 is activated (24). 
Hence, miRNAs appear to promote the endocrine cell fate by 
repressing neuronal gene activity in endocrine progenitors. 
Overall, these findings illustrate the important role of miRNAs 
in β-cell development and maintenance.
To figure out which specific miRNAs are involved in 
pancreas development and/or β-cell survival, the expression 
profile of miRNAs in the developing pancreas as well as α- 
and β -cells of different species has been investigated (25-30). 
One of the most studied miRNAs during pancreas develop-
ment is miR-375. MiR-375 is highly expressed in pancreatic 
islet (29,31) and was shown to regulate insulin secretion in 
primary islet explants, as well as in MIN6 β-cells by inhibiting 
mytropin (Mtpn) (29). Knockdown of miR-375 in zebrafish 
using morpholinos resulted in a dramatic malformation of en-
docrine cells in the developing embryo at 48 and 72 hours post 
fertilization (hpf). The knockdown embryos show scattered 
insulin-, glucagon-, PP- and SST-positive cells while the WT 
embryos exhibit single clusters of hormone-expressing cells 
(28).  At 24 hpf, the expression of the pancreatic hormones 
is still normal in the knockdown embryos, suggesting a more 
prominent role for miR-375 in maintenance of endocrine cell 
fate and tissue identity than in early endocrine cell develop-
ment (28). Analysis of mice lacking miR-375 support these 
findings, and knockout animals display a reduced number of 
β-cells, whereas the pancreatic α-cell content is increased. Ac-
cordingly, these mice suffer from hyperglycemia that is mainly 
caused by hyperglucagonemia (32). In summary, miR-375 
appears to target genes that are necessary for the control of 
endocrine cell identity and/or proliferation. However, direct 
targets of miR-375 remain to be identified. It should be noted 
that miR-375 is not only important for pancreas development, 
but it also required for maintaining β-cell physiology. Silencing 
of miR-375 in MIN6 and mouse primary β-cells is accompa-
nied with increased glucose-stimulated insulin secretion (29). 
MiR-7 is also highly expressed during pancreas develop-
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Figure 1: miRNAs involved in pancreas development, β-cell regeneration, and insulin secretion.
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ment in human and mice (33-36). In situ hybridization studies 
showed that miR-7 is only expressed in endocrine but not in 
exocrine pancreatic cells, suggesting a possible role of miR-7 
in endocrine development (33, 35). MiR-7 is already detected 
in Ngn3-positive endocrine progenitors in mice (35), but not 
in humans (33). Knockdown of miR-7 in mice provokes a 
reduction in insulin production and decreased β-cell content, 
while the transcript level of the other endocrine hormones 
(glucagon, somatostatin and pancreatic polypeptide) remains 
unaffected (36). These results are in contrast to a more recent 
study where silencing of miR-7 in primary pancreatic ex-
plants is accompanied with increased number of both insulin 
and glucagon expressing cells (35). These divergent findings 
might be related to the choice of the experimental systems, 
performed in vivo (36) and ex vivo (35), and at different de-
velopmental stages. This may indicate that miR-7 has distinct 
roles at different stages of pancreatic endocrine genesis. MiR-7 
might promote differentiation, and/or survival of endocrine 
cell survival.  Overexpression of miR-7 in ex vivo pancreatic 
explants provokes a phenotype that is reminiscent of heterozy-
gous Pax6-deficient mice, where amongst others the levels 
of insulin and MafB are down regulated (35). Moreover the 
level of Pax6 transcripts was significantly reduced (35). MiR-
7 overexpression in Pdx-1 progenitors in mice corroborates 
the findings from explant culture. Further, molecular analyses 
provide evidence that miR-7 controls and refines Pax6 levels 
in the endocrine pancreas (35). 
MiR-124a is expressed in the early developing pancreas 
and appears to regulate Foxa2 expression in pancreatic MIN6 
β-cells (37). Foxa2 itself is involved in pancreas development 
by regulating Pdx1 expression (38). Following knockdown of 
miR-124a in MIN6 cells Pdx1 and Insulin levels are augment-
ed, while its overexpression results in an opposite alteration. 
MiR-124a was also suggested to modulate Insulin secretion 
in MIN6 cells (37).  Notwithstanding, miR-124a function in 
pancreas development remains obscure. In addition to the 
discussed miRNAs miR-495 and miR-218 were also suggested 
to be involved in pancreas genesis. They target the 3’-UTR 
region of HNF-6, which is an important transcription factor 
required for correct timing of pancreas specification (39, 40).
Although all of the discussed studies clearly demonstrate 
the importance for miRNAs during pancreas development, 
their proper function and targeting pathways in this context 
remain still unclear. Therefore, it is crucial to investigate their 
targets to get further insights into the gene networks controlling 
pancreas and especially β-cell development. 
miRNAs IN INSuLIN SECRETION
As mentioned above, one of the direct targets of miR-375 is 
myotropin (Mtpn). Mtpn is involved in insulin secretion (29). 
Overexpression and inhibition of miR-375 in MIN6 cell leads 
to down and enhanced insulin secretion, respectively. Knock-
down of Mtpn itself correlates with miR-375 forced expression 
(29). How Mtpn exactly regulates Insulin secretion remains 
unclear and needs further investigation.
As already mentioned, miR-124a regulates Foxa2 ex-
pression in the insulinoma pancreatic b-cell line MIN6. As 
Foxa2 plays prominent role in Insulin secretion and glucose 
homeostasis (41), it is conceivable to speculate that miR-
124a might also be involved in Insulin secretion pathway. 
Accordingly, it was shown that miR-124a and miR-96 
modulate protein levels of SNAP25, Rab3A, Rab27A and 
Noc2, which are all known to be engaged in the process of 
insulin secretion (42).
Overexpression of miR-9 in β-cells and the pancreatic 
β-cell line Ins-1 leads to impairment of glucose-stimulated 
insulin secretion through regulation of onecut 2 (43). Onecut 
2 modulates granuphilin expression, which plays important 
role in exocytosis. Overexpression of miR-9 reduces onecut 
2 expression, which in turn causes accumulation of higher 
granuphilin level that leads to impaired exocytosis (43). These 
results demonstrate that miR-9 negatively regulates insulin 
secretion. 
The miR-29 gene family consists of three paralogs: miR-
29a, miR-29b and miR-29c. Raising the level of one of these 
miRNAs in MIN6, Ins-1E or primary mouse islet cells leads 
to reduction of glucose-induced insulin secretion (44,45). 
As shown for miR-9, the expression level of onecut 2 is de-
creased upon miR-29 overexpression, possibly justifying the 
observed phenotype in glucose-stimulated Insulin secretion 
(45). Moreover miR-29a directly targets syntaxin-1a, another 
protein implicated in insulin exocytosis (46). 
Another miRNA involved in insulin secretion is miR-184, 
which is enriched in human pancreatic islets (47). MiR-184 
regulates glucose-stimulated insulin secretion through repress-
ing Scl2a22 (48), which plays an essential role in glucose-
stimulated insulin secretion of β-cells (49).
Overall it is clear that distinct miRNAs have different targets 
in the Insulin secretion network. In order to fully understand 
the underlying mechanisms that make a functional glucose-
responsive β-cell, it is necessary to uncover the exact function 
of miRNAs that regulate this process by fine-tuning the level 
of distinct modulators. 
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miRNAs IN β-CELL REGENERATION
Proliferation of β-cells has been described in adult rodents 
in response to physiological increased metabolic demands in 
obesity, and pregnancy. β-cell regeneration was shown to occur 
following pathophysiological conditions caused by pancreatic 
injury or disease (50,51). Several animal models are used to 
study the mechanisms underlying β-cell regeneration, and it 
is now believed that the regenerative capacity, and the mecha-
nisms through which it takes place, are highly dependent on 
the extent of β-cell loss, and type of injury. Three main mecha-
nisms were suggested to contribute to β-cell regeneration in 
adult rodents. In most of studies, adaptive β-cell proliferation 
predominantly represents the major source for increased β-cell 
mass upon β-cell depletion (52-54). Furthermore, higher meta-
bolic demands during pregnancy and insulin resistance can 
also induce β-cell proliferation, and leads to increased β-cell 
mass, which then can compensate for the lower peripheral 
sensitivity (55,56). Some other studies have shown that β-cells 
can be differentiated from progenitor cells in pancreatic duct, 
as they do during embryonic development (57-60). Recently, 
some groups have revealed the potential of α-cells to switch 
their fate and transdifferentiate to β-cells in extreme β-cell loss 
condition (61) (62). Emerging evidences suggest that miRNA 
can mediate the responses to different types of cellular stresses 
through post-transcriptional modification of mRNAs, which 
leads to changes in gene expression patterns and thereby ac-
tivation and inhibition of different biological processes in the 
cells (63). For example, miRNAs induced by inflammation 
can guide the cell to mediate the inflammatory responses and 
to switch them off later (64). In another interesting example, 
an endothelial-specific miRNA mediates stress-induced pro-
liferation, angiogenesis, and wound repair (65).
There are few reports on miRNAs regulating β-cell stress 
response and regeneration. MiR-375 is an islet-specific miR-
NA that has an essential role in maintenance of α- and β-cell 
mass, as discussed above. Additionally, miR-375 is increased 
in the islet of ob/ob mice and its deficiency impairs both basal 
proliferation and the adaptive proliferation of β-cells induced 
by Insulin resistance and obesity. Although under normal 
conditions, minor reduction in β-cell mass did not have a 
severe impact on plasma Insulin level, lack of compensatory 
proliferation in miR-375 KO Insulin resistant obese mice 
leads to a drastic decrease in β-cell mass and Insulin level 
compared to the ob/ob littermates. By comparing the gene 
expression pattern of pancreatic islets from miR-375 KO and 
wildtype littermates to find potential miRNA targets among 
the genes upregulated in KO islet, it was concluded that miR-
375 regulates a cluster of genes that are negatively regulating 
proliferation- and growth-related pathways. Cadm1, Rasd1, 
Eef1e1, C1qbp, Aifm1, Rgs16, Cav1, Id3, Smarca2, HuD, 
and Nnat are the potential target genes that were upregulated 
in miR-375 knockout islets (32). It is also shown that miR-
375 can inhibit tumor cell growth in different carcinoma cell 
lines (66,67) and its expression is downregulated in pancreatic 
cancer (68). 
Another abundant miRNA in islets is miR-7 (25,33), which 
was recently shown to target different components of mTOR 
signaling pathway, and thereby negatively regulates β-cell 
proliferation in mouse and human. The mammalian target 
of rapamycin (mTOR) is a kinase that forms two distinct 
complexes known as mTORC1 and mTORC2 (69). mTOR 
signaling pathway links the external and internal signaling 
pathway to modulation of cell growth and proliferation, cell 
survival, and metabolism. mTOR  is mainly regulated by 
nutrients and growth factors and initiates the proliferative or 
anti-proliferative responses based on the growth-promoting or 
growth-suppressing signals (70, 71). Constitutive activation of 
mTORC1 in pancreatic β-cells leads to increased β-cell pro-
liferation, β-cell mass, and Insulin secretion in the first phase. 
This is then followed by increased β-cell apoptosis and hyper-
glycemia due to cellular exhaustion (72,73). Consistently, loss 
of mTORC2 results in decreased β-cell mass and proliferation 
that eventually causes hyperglycemia and glucose intolerance 
(71,74). These observations clearly demonstrate that the level 
of several components of mTOR signaling pathway should be 
finely controlled at different cellular status, to keep a healthy 
balance between proliferation and survival.
As mentioned above, self-replication of pre-existing β-cells 
is the major mechanism replenishing β-cell mass in adult 
pancreas. But, there are some evidences showing that β-cell re-
generation induced by certain type of damage and injury might 
recapitulate the developmental events in embryonic pancreas 
(51). For example, many transcription factors that play essen-
tial roles in pancreas development such as Foxa2, Pdx1 and 
also Ngn3 that is required for endocrine lineage specification, 
are reactivated after 70% pancreatectomy or pancreatic duct 
ligation. In some cases, Ngn3 expressing cells were detected 
in the duct epithelium and they also seemed to contribute to 
the newly formed β-cell population (60,75). Other studies have 
challenged the contribution of Ngn3 expressing cells to β-cell 
lineage (76,77). Importantly, further characterization of expres-
sion profile of regenerating pancreata suggested that Ngn3 
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mRNA level is post-transcriptionally regulated by miR-15a, 
miR-15b, miR-16 and miR-195, which are highly up-regulated 
in regenerating pancreas (78). Such mechanism might limit or 
suppress β-cell neogenesis via endocrine progenitors in adult 
life. It should be noted that the promoter-based strategies used 
for monitoring the re-activation of Ngn3 can only represent 
the promoter activation and mRNA expression (60,75) and do 
not take into account the miRNA-mediated post-transcription 
regulation imposed on Ngn3 transcripts. This might explain 
the controversial observations in different studies.
In a recent study, Jacovetti et al (80) have identified a set of 
miRNAs that are differentially expressed in the islets of preg-
nant rats. MiR-218, miR-338-3p, and miR-874 are found to be 
significantly downregulated at day 14 of gestation in pregnant 
rats compared to the age-matched non-pregnant females. In the 
same animals, miR-144 and miR-451 levels are significantly 
upregulated. Interestingly, they have observed that downregu-
lation of miR-338-3p increases proliferation rate of INS832/13 
cells and dissociated rat β-cells, but not human β-cells. Ad-
ditionally, they have shown that reduction of miR-338-3p or 
increased level of miR-451 can protect cultured rat and human 
islet cells against pro-apoptotic effects exerted by exposure 
to pro-inflammatory cytokines. Further investigations showed 
that miR-338-3p level is also reduced in Insulin resistant db/
db and HFD-fed mice. It was observed that treatment of rat 
and human islets with incretin hormone glucagon-like peptide 
1 analog, Exendin-4, or pregnancy associated hormone17-β 
estradiol (79) decreases miR-338-3p level. They observed that 
the inhibition of miR-338-3p resembles the effect of GLP1 on 
β- cells and upregulates Igf1r and Irs2 expression. So, they 
hypothesized that miR-338-3p downregulation is associated 
with the compensatory β-cell mass expansion, and estrogens 
and incretin hormones mediate it (80).
CONCLuSION
Deregulated expression of miRNAs has been associated with 
many pathological situations and diseases. In many cases, it 
is not clear if the alteration in miRNA expression is in fact 
the primary cause or the subsequent effect of the disease. As 
discussed above, it appears that miRNAs may control vari-
ous important aspects of β-cell development, function, and 
regeneration (Fig. 1). It should be noted that maintenance 
of homeostatic condition is a result of interplay of several 
genes, and miRNAs fine-tuning their levels at different states. 
Any imbalance in the level of these players could lead to 
development of complex diseases such as type 1 and type 2 
diabetes. Therefore, getting more insights into the molecular 
mechanisms and linking the different contributors of these 
gene-miRNA networks is of fundamental importance for de-
veloping novel therapeutic approaches for diabetes. Finally, it 
is interesting to note that recent studies have highlighted the 
presence of miRNAs in body fluids and represented them as a 
new type of biomarkers for early diagnosis of diseases (81-83).
ACkNOwLEDGEMENTS
We would like to thank the Max-Planck Society, the Juvenile 
Diabetes Research Foundation (JDRF), and the BMBF (FKZ 
01KU0906) for financial support.
REFERENCES 
1. Pan FC, Wright C. Pancreas organogenesis: from bud to 
plexus to gland. Dev Dyn  2011; 240:  530-565.
2. Champeris ST, Jones PM, Generating pancreatic beta-cells 
from embryonic stem cells by manipulating signaling 
pathways. J Endocrinol  2010; 206: 13-26.
3. Limbert C, G. Path, F. Jakob, J. Seufert. Beta-cell replace-
ment and regeneration: Strategies of cell-based therapy for 
type 1 diabetes mellitus. Diabetes Res Clin Pract 2008; 
79: 389-399.
4. Collombat P, A. Mansouri, J. Hecksher-Sorensen, P. Se-
rup, J. Krull, G. Gradwohl, et al. Opposing actions of Arx 
and Pax4 in endocrine pancreas development. Genes Dev 
2003; 17: 2591-2603.
5. Collombat P, J. Hecksher-Sorensen, V. Broccoli, J. Krull, 
I. Ponte, T. Mundiger, et al. The simultaneous loss of Arx 
and Pax4 genes promotes a somatostatin-producing cell 
fate specification at the expense of the alpha- and beta-cell 
lineages in the mouse endocrine pancreas. Development 
2005; 132: 2969-2980.
6. Gradwohl G, A. Dierich, M. LeMeur, F. Guillemot.
Neurogenin3 is required for the development of the four 
endocrine cell lineages of the pancreas. Proc Natl Acad 
Sci USA  2000; 97:  1607-1611.
7. Gu G, Dubauskaite J, Melton DA. Direct evidence for the 
pancreatic lineage: NGN3+ cells are islet progenitors and 
are distinct from duct progenitors. Development  2002; 
129:  2447-2457.
8. Holland AM, L.J. Gonez, G. Naselli, R.J. Macdonald, 
L.C. Harrison. Conditional expression demonstrates the 
role of the homeodomain transcription factor Pdx1 in 
maintenance and regeneration of beta-cells in the adult 
pancreas. Diabetes  2005; 54:  2586-2595.
63
Biomed Rev 24, 2013
miRNAs in endocrine pancreas
9. Johansson KA, U. Dursun, N. Jordan, G. Gu, F. Beermann, 
G. Gradwohl, et al. Temporal control of neurogenin3 activ-
ity in pancreas progenitors reveals competence windows 
for the generation of different endocrine cell types. Dev 
Cell  2007; 12:  457-465.
10. Sander M, L. Sussel, J. Conners, D. Scheel, J. Kalamaras, 
F. Dela Cruz, et al. Homeobox gene Nkx6.1 lies down-
stream of Nkx2.2 in the major pathway of beta-cell forma-
tion in the pancreas. Development  2000; 127:  5533-5540.
11. Sosa-Pineda B, K. Chowdhury, M. Torres, G. Oliver, P. 
Gruss. The Pax4 gene is essential for differentiation of 
insulin-producing beta cells in the mammalian pancreas. 
Nature  1997; 386:  399-402.
12. Sosa-Pineda B. The gene Pax4 is an essential regulator 
of pancreatic beta-cell development. Mol Cells  2004; 18: 
289-294.
13. Stoffers DA, M.K. Thomas,  J.F. Habener. Homeodomain 
protein IDX-1: a master regulator of pancreas develop-
ment and insulin gene expression. Trends Endocrinol 
Metab  1997; 8:  145-151.
14. Lee RC, R.L. Feinbaum, V. Ambros. The C. elegans het-
erochronic gene lin-4 encodes small RNAs with antisense 
complementarity to lin-14. Cell  1993; 75:  843-854.
15. Bartel DP. MicroRNAs: genomics, biogenesis, mecha-
nism, and function. Cell  2004; 116:  281-297.
16. Krol J, I. Loedige, W. Filipowicz. The widespread regu-
lation of microRNA biogenesis, function and decay. Nat 
Rev Genet  2010; 11:  597-610.
17. Ferland-McCollough D, S.E. Ozanne, K. Siddle, A.E. 
Willis, M. Bushell. The involvement of microRNAs in 
type 2 diabetes. Biochem Soc Trans  2010; 38:  1565-
1570.
18. Guay C, E. Roggli, V. Nesca, C. Jacovetti, R. Regazz.
Diabetes mellitus, a microRNA-related disease? Transl 
Res  2011; 157:  253-264.
19. Poy MN, M. Spranger, M. Stoffel. MicroRNAs and the 
regulation of glucose and lipid metabolism. Diabetes Obes 
Metab  2007; 9 (Suppl 2):  67-73.
20. Lynn FC, P. Skewes-Cox, Y. Kosaka, M.T. McManus, B.D. 
Harfe, M.S. German. MicroRNA expression is required 
for pancreatic islet cell genesis in the mouse. Diabetes 
2007; 56:  2938-2945.
21. Melkman-Zehavi T, R. Oren, S. Kredo-Russo, T. Shapira, 
A.D. Mandelbaum, N. Rivkin, et al. miRNAs control in-
sulin content in pancreatic beta-cells via downregulation 
of transcriptional repressors. EMBO J  2011; 30:  835-845.
22. Mandelbaum AD, T. Melkman-Zehavi, R. Oren, S. Kredo-
Russo, T. Nir, Y. Dor, et al. Dysregulation of Dicer1 in beta 
cells impairs islet architecture and glucose metabolism. 
Exp Diabetes Res  2012; 2012:  470302.
23. Kalis M, C. Bolmeson, J.L. Esguerra, S. Gupta, A. Edlund, 
N. Tormo-Badia, et al. Beta-cell specific deletion of Dicer1 
leads to defective insulin secretion and diabetes mellitus. 
PLoS One  2011; 6:  e29166.
24. Kanji MS, M.G. Martin, A. Bhushan. Dicer1 is required 
to repress neuronal fate during endocrine cell maturation. 
Diabetes  2013; 62:  1602-1611.
25. Bravo-Egana V, S. Rosero, R.D. Molano, A. Pileggi, C. 
Ricordi, J. Dominguez-Bendala, et al. Quantitative dif-
ferential expression analysis reveals miR-7 as major islet 
microRNA. Biochem Biophys Res Commun  2008; 366: 
922-926.
26. Joglekar MV, V.S. Parekh, A.A. Hardikar. New pancreas 
from old: microregulators of pancreas regeneration. Trends 
Endocrinol Metab  2007; 18:  393-400.
27. Klein D, R. Misawa, V. Bravo-Egana, N. Vargas, S. Ros-
ero, J. Piroso, et al. MicroRNA expression in alpha and 
beta cells of human pancreatic islets. PLoS One  2013; 8: 
e55064.
28. Kloosterman WP, A.K. Lagendijk, R.F. Ketting, J.D. 
Moulton, R.H. Plasterk. Targeted inhibition of miRNA 
maturation with morpholinos reveals a role for miR-375 
in pancreatic islet development. PLoS Biol  2007; 5:  e203.
29. Poy MN, L. Eliasson, J. Krutzfeldt, S. Kuwajima, X. Ma, 
P.E. Macdonald, et al. A pancreatic islet-specific microRNA 
regulates insulin secretion. Nature  2004; 432:  226-230.
30. Rosero S, V. Bravo-Egana, Z. Jiang, S. Khuri, N. Tsinore-
mas, D. Klein, et al. MicroRNA signature of the human 
developing pancreas. BMC Genomics  2010; 11:  509.
31. Avnit-Sagi T, L. Kantorovich, S. Kredo-Russo, E. Horn-
stein, M.D. Walker. The promoter of the pri-miR-375 gene 
directs expression selectively to the endocrine pancreas. 
PLoS One  2009; 4(4):  e5033.
32. Poy MN, J. Hausser, M. Trajkovski, M. Braun, S. Collins, 
P. Rorsman, et al. miR-375 maintains normal pancreatic 
alpha- and beta-cell mass. Proc Natl Acad Sci USA  2009; 
106:  5813-5818.
33. Correa-Medina M, V. Bravo-Egana, S. Rosero, C. Ricordi, 
H. Edlund, J. Diez, et al. MicroRNA miR-7 is prefer-
entially expressed in endocrine cells of the developing 
and adult human pancreas. Gene Expr Patterns  2009; 9: 
193-199.
64
Biomed Rev 24, 2013
Rabe, Shamsi and Mansouri
34. Joglekar MV, Joglekar VM, Hardikar AA. Expression 
of islet-specific microRNAs during human pancreatic 
development. Gene Expr Patterns  2009; 9:  109-113.
35. Kredo-Russo S, A.D. Mandelbaum, A. Ness, I. Alon, K.A. 
Lennox, M.A. Behlke, et al. Pancreas-enriched miRNA 
refines endocrine cell differentiation. Development  2012; 
139:  3021-3031.
36. Nieto M, P. Hevia, E. Garcia, D. Klein, S. Alvarez-Cubela, 
V. Bravo-Egana, et al. Antisense miR-7 impairs insulin 
expression in developing pancreas and in cultured pan-
creatic buds. Cell Transplant  2012; 21:  1761-1774.
37. Baroukh N, M.A. Ravier, M.K. Loder, E.V. Hill, A. Bou-
nacer, R. Scharfmann, et al. MicroRNA-124a regulates 
Foxa2 expression and intracellular signaling in pancreatic 
beta-cell lines. J Biol Chem  2007; 282:  19575-19588.
38. Gao N, J. LeLay, M.Z. Vatamaniuk, S. Rieck, J.R. 
Friedman, K.H. Kaestner. Dynamic regulation of Pdx1 
enhancers by Foxa1 and Foxa2 is essential for pancreas 
development. Genes Dev  2008; 22:  3435-3448.
39. Jacquemin P, F.P. Lemaigre. G.G. Rousseau. The Onecut 
transcription factor HNF-6 (OC-1) is required for timely 
specification of the pancreas and acts upstream of Pdx-1 in 
the specification cascade. Dev Biol  2003; 258(1):  105-116.
40. Simion A, I. Laudadio, P.P. Prevot, P. Raynaud, F.P. Le-
maigre and P. Jacquemin. MiR-495 and miR-218 regulate 
the expression of the Onecut transcription factors HNF-6 
and OC-2. Biochem Biophys Res Commun  2010; 391: 
293-298.
41. Gao N, P. White, N. Doliba, M.L. Golson, F.M. Matschin-
sky,  K.H. Kaestner. Foxa2 controls vesicle docking and 
insulin secretion in mature Beta cells. Cell Metab  2007; 
6:  267-279.
42. Lovis P, S. Gattesco, R. Regazzi. Regulation of the ex-
pression of components of the exocytotic machinery of 
insulin-secreting cells by microRNAs. Biol Chem  2008; 
389:  305-312.
43. Plaisance V, A. Abderrahmani, V. Perret-Menoud, P. Jac-
quemin, F. Lemaigre R. Regazzi. MicroRNA-9 controls 
the expression of Granuphilin/Slp4 and the secretory 
response of insulin-producing cells. J Biol Chem  2006; 
281:  26932-26942.
44. Bagge A, T.R. Clausen, S. Larsen, M. Ladefoged, M.W. 
Rosenstierne, L. Larsen, et al. MicroRNA-29a is up-
regulated in beta-cells by glucose and decreases glucose-
stimulated insulin secretion. Biochem Biophys Res Com-
mun  2012; 426:  266-272.
45. Roggli E, S. Gattesco, D. Caille, C. Briet, C. Boitard, P. 
Meda, et al. Changes in microRNA expression contribute 
to pancreatic beta-cell dysfunction in prediabetic NOD 
mice. Diabetes  2012; 61:  1742-1751.
46. Bagge A, C.M. Dahmcke, L.T. Dalgaard. Syntaxin-1a is 
a direct target of miR-29a in insulin-producing beta-cells. 
Horm Metab Res  2013; 45:  463-466.
47. Bolmeson C, J.L. Esguerra, A. Salehi, D. Speidel, L. Elias-
son, C.M. Cilio. Differences in islet-enriched miRNAs in 
healthy and glucose intolerant human subjects. Biochem 
Biophys Res Commun  2011; 404:  16-22.
48. Morita S, T. Horii, M. Kimura, I. Hatada. MiR-184 regu-
lates insulin secretion through repression of Slc25a22. 
PeerJ  2013; 1:  e162.
49. Casimir M, F.M. Lasorsa, B. Rubi, D. Caille, F. Palmieri, 
P. Meda, et al. Mitochondrial glutamate carrier GC1 
as a newly identified player in the control of glucose-
stimulated insulin secretion. J Biol Chem  2009; 284: 
25004-25014.
50. Banerjee M, M. Kanitkar, R.R. Bhonde. Approaches 
towards endogenous pancreatic regeneration. Rev Diabet 
Stud  2005; 2(3):  165-176.
51. Collombat P, X. Xu, H. Heimberg and A. Mansouri. Pan-
creatic beta-cells: from generation to regeneration. Semin 
Cell Dev Biol  2010; 21:  838-844.
52. Brennand K, D. Huangfu, D. Melton. All beta cells con-
tribute equally to islet growth and maintenance. PLoS Biol 
2007; 5:  e163.
53. Dor Y, J. Brown, O.I. Martinez, D.A. Melton. Adult pan-
creatic beta-cells are formed by self-duplication rather 
than stem-cell differentiation. Nature  2004; 429:  41-46.
54. Georgia S, Bhushan A. Beta cell replication is the primary 
mechanism for maintaining postnatal beta cell mass. J Clin 
Invest  2004; 114:  963-968.
55. Ogino J, K. Sakurai, K. Yoshiwara, Y. Suzuki, N. Ishizuka, 
N. Seki, et al. Insulin resistance and increased pancreatic 
beta-cell proliferation in mice expressing a mutant insulin 
receptor (P1195L). J Endocrinol  2006; 190:  739-747.
56. Parsons JA, T.C. Brelje, R.L. Sorenson. Adaptation of 
islets of Langerhans to pregnancy: increased islet cell 
proliferation and insulin secretion correlates with the onset 
of placental lactogen secretion. Endocrinology  1992; 130: 
1459-1466.
57. Al-Hasani K, A. Pfeifer, M. Courtney, N. Ben-Othman, E. 
Gjernes, A. Vieira, et al. Adult duct-lining cells can repro-
gram into beta-like cells able to counter repeated cycles of 
toxin-induced diabetes. Dev Cell  2013; 26:  86-100.
65
Biomed Rev 24, 2013
miRNAs in endocrine pancreas
58. Collombat P, X. Xu, P. Ravassard, B. Sosa-Pineda, S. Dus-
saud, N. Billestrup, et al. The ectopic expression of Pax4 
in the mouse pancreas converts progenitor cells into alpha 
and subsequently beta cells. Cell  2009; 138:  449-462.
59. Bonner-Weir S, A. Inada, S. Yatoh, W.C. Li, T. Aye, E. 
Toschi, et al. Transdifferentiation of pancreatic ductal cells 
to endocrine beta-cells. Biochem Soc Trans  2008; 36(Pt 
3):  353-356.
60. Xu X, J. D’Hoker, G. Stange, S. Bonne, N. De Leu, X. 
Xiao, et al. Beta cells can be generated from endogenous 
progenitors in injured adult mouse pancreas. Cell  2008; 
132:  197-207.
61. Chung CH, E. Hao, R. Piran, E. Keinan, F. Levine. Pan-
creatic beta-cell neogenesis by direct conversion from 
mature alpha-cells. Stem Cells  2010; 28:  1630-1638.
62. Thorel F, V. Nepote, I. Avril, K. Kohno, R. Desgraz, S. 
Chera, et al. Conversion of adult pancreatic alpha-cells to 
beta-cells after extreme beta-cell loss. Nature  2010; 464: 
1149-1154.
63. Leung AK, Sharp PA. MicroRNA functions in stress 
responses. Mol Cell  2010; 40:  205-215.
64. O’Connell RM, K.D. Taganov, M.P. Boldin, G. Cheng, 
D. Baltimore. MicroRNA-155 is induced during the 
macrophage inflammatory response. Proc Natl Acad Sci 
USA  2007; 104:  1604-1609.
65. Wang S, A.B. Aurora, B.A. Johnson, X. Qi, J. McAnally, 
J.A. Hill, et al. The endothelial-specific microRNA miR-
126 governs vascular integrity and angiogenesis. Dev Cell 
2008; 15:  261-271.
66. He XX, Y. Chang, F.Y. Meng, M.Y. Wang, Q.H. Xie, F. 
Tang, et al. MicroRNA-375 targets AEG-1 in hepatocel-
lular carcinoma and suppresses liver cancer cell growth 
in vitro and in vivo. Oncogene  2012; 31:  3357-3369.
67. Kong KL, D.L. Kwong, T.H. Chan, S.Y. Law, L. Chen, 
Y. Li, et al. MicroRNA-375 inhibits tumour growth and 
metastasis in oesophageal squamous cell carcinoma 
through repressing insulin-like growth factor 1 receptor. 
Gut  2012; 61:  33-42.
68. Zhou J, S. Song, J. Cen, D. Zhu, D. Li and Z. Zhang, 
MicroRNA-375 is downregulated in pancreatic cancer 
and inhibits cell proliferation in vitro. Oncol Res  2012; 
20:  197-203.
69. Weichhart T. Mammalian target of rapamycin: a signaling 
kinase for every aspect of cellular life. Methods Mol Biol 
2012; 821:  1-14.
70. Hay N, and  Sonenberg N. Upstream and downstream of 
mTOR. Genes Dev  2004; 18:  1926-1945.
71. Laplante M, Sabatini DM. mTOR signaling in growth 
control and disease. Cell  2012; 149:  274-293.
72. Rachdi L, N. Balcazar, F. Osorio-Duque, L. Elghazi, A. 
Weiss, A. Gould, et al. Disruption of Tsc2 in pancreatic 
beta cells induces beta cell mass expansion and improved 
glucose tolerance in a TORC1-dependent manner. Proc 
Natl Acad Sci USA  2008; 105:  9250-9255.
73. Shigeyama Y, T. Kobayashi, Y. Kido, N. Hashimoto, S. 
Asahara, T. Matsuda, et al. Biphasic response of pancreatic 
beta-cell mass to ablation of tuberous sclerosis complex 
2 in mice. Mol Cell Biol  2008; 28:  2971-2979.
74. Gu Y, J. Lindner, A. Kumar, W. Yuan and M.A. Magnuson.
Rictor/mTORC2 is essential for maintaining a balance 
between beta-cell proliferation and cell size. Diabetes 
2011; 60:  827-837.
75. Van de Casteele M, G. Leuckx, L. Baeyens, Y. Cai, Y. 
Yuchi, V. Coppens, et al. Neurogenin 3+ cells contribute 
to beta-cell neogenesis and proliferation in injured adult 
mouse pancreas. Cell Death Dis  2013; 4:  e523.
76. Lee CS, D.D. De Leon, K.H. Kaestner and D.A. Stof-
fers. Regeneration of pancreatic islets after partial pan-
createctomy in mice does not involve the reactivation of 
neurogenin-3. Diabetes  2006; 55:  269-272.
77. Xiao X, Z. Chen, C. Shiota, K. Prasadan, P. Guo, Y. El-
Gohary, et al. No evidence for beta cell neogenesis in 
murine adult pancreas. J Clin Invest  2013; 123:  2207-2217.
78. Joglekar MV, V.S. Parekh, S. Mehta, R.R. Bhonde and 
A.A. Hardikar. MicroRNA profiling of developing and 
regenerating pancreas reveal post-transcriptional regula-
tion of neurogenin3. Dev Biol  2007; 311:  603-612.
79. Nadal A, P. Alonso-Magdalena, S. Soriano, A.B. Ropero, 
I. Quesada. The role of oestrogens in the adaptation of 
islets to insulin resistance. J Physiol  2009; 587(Pt 21): 
5031-5037.
80. Jacovetti C, Abderrahmani A, Parnaud  G, Jonas JC, Peyot 
ML, Cornu M, et al. MicroRNAs contribute to compensa-
tory beta cell expansion during pregnancy and obesity. J 
Clin Invest  2012; 122:  3541-3551.
81. Anindo MI, Yaqinuddin A. Insights into the potential use 
of microRNAs as biomarker in cancer. Int J Surg  2012; 
10:  443-449.
82. Etheridge A, I. Lee, L. Hood, D. Galas, K. Wang. Extra-
cellular microRNA: a new source of biomarkers. Mutat 
Res  2011; 717:  85-90.
83. Gilad S, E. Meiri, Y. Yogev, S. Benjamin, D. Lebanony, 
N. Yerushalmi, et al. Serum microRNAs are promising 
novel biomarkers. PLoS One  2008; 3:  e3148.
